Heike Krupka serves as Chief Development Officer at CatalYm. She brings over two decades of leadership experience in drug development in hematology, oncology, cell therapy, and immunology across the full product life cycle—from discovery through clinical testing to market launch. Heike joins CatalYm from Bristol Myers Squibb, where she served as Vice President and Head of Project Management for Hematology, Oncology, and Cell Therapy, following her role as Vice President and Early Development Program Leader for Cell Therapy and Immuno-Oncology, advancing alnuctamab and arlo-cel towards pivotal development. Previously, she oversaw the advancement of key products as Asset Team Leader at Pfizer, including elranatamab (ELREXFIO®) and sasanlimab. Prior to Pfizer she contributed to the clinical development of multiple novel therapeutics at KaloBios and Genentech/Roche (POLIVY®, GAZYVA®). Heike holds a PhD from the Technical University Munich and the Max Planck Institute for Biochemistry and a degree in chemistry from Ludwig-Maximilians-University in Munich, Germany.